Oligonucleotides for Cardiovascular and Metabolic Disease Summit

Memo

Developed from research with industry leaders, including AstraZeneca, Ionis, and Amgen, this intimate digital conference will pre-competitively advance ASO, RNAi, and RNA therapeutics beyond the liver, by comprehensively analyzing pioneering research and the latest data specific to cardiovascular and cardiometabolic disease in both rare and chronic settings. Hear world-class insights from bench to bedside and troubleshoot clinical challenges with other stakeholders, including maximizing on-target delivery, achieving appropriate dosage and administration, and optimizing clinical trial design to accelerate the development of life-changing therapies for millions of patients worldwide. Join over 40 other oligonucleotide and cardiometabolic drug developers at this uniquely concentrated conference dedicated to advancing the next generation of oligonucleotide therapeutics for cardiometabolic disease. URLs:Tickets: https://go.evvnt.com/660158-2?pid=5569Brochure: https://go.evvnt.com/660158-3?pid=5569 Prices:Full Conference (Digital Summit) - Industry Pricing: USD 1699.0,Full Conference (Digital Summit) - Standard Pricing: USD 2099.0,Full Conference (Digital Summit) - Academic Pricing: USD 1199.0,Early Bird - Full Conference Industry Pricing: USD 599.0 Speakers: Dan Swerdlow, Senior Medical Director, Silence Therapeutics, David Blakey, Chief Scientific Officer, MiNA Therapeutics, Elena Feinstein, Chief Scientific Officer, Quark Pharmaceuticals, Marcus Schindler, Senior Vice President, Head of Global Drug Discovery, Novo Nordisk, Marie Wikstrom, Lindholm Vice President, Head of Molecular Design, Silence Therapeutics, Patrik Anderson, RNA Therapeutics Safety Lead, AstraZeneca, Piotr Kowalski, HRB Emerging Investigator for Health, Lecturer in Advanced Therapies, University College Cork, Richard Geary, Executive Vice President, Drug Development, Ionis Pharmaceuticals, Robert Dullea, Senior Medical Director, Pfizer, Rusty Montgomery, Director of Research, miRagen Therapeutics, Samir Ounzain, Chief Executive Officer and Scientific Co-Founder, HAYA Therapeutics, Sandor Batkai, Head of Science, Co-Founder and Project Co-Director, Cardior Pharmaceuticals, Tom Thuren, Metabolism Therapeutic Area Head, Cardio-Metabolic Development Unit, Novartis, Troels Koch, Chief Technology Officer, Senior Vice President Science and Technology, Inexos Therapeutics Time: 07:00 - 16:30